NCT01724489

Study of Growth Hormone and Bone in Obesity

Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Obesity is an important risk factor for osteoporosis and fractures. With the growing prevalence of obesity in the U.S., understanding the pathophysiology of bone loss in this population is of importance to public health. Growth hormone (GH) is a critical mediator of bone homeostasis and is markedly reduced in obesity. Our preliminary data suggest an important role for the GH/insulin-like growth factor 1 (IGF-1) system in the pathogenesis of bone loss in obesity. The development of novel imaging techniques provides an opportunity to investigate the effects of GH on skeletal structure and strength, which will provide insights into the pathogenesis of obesity related bone loss. Understanding the pathophysiology of bone loss in obesity may help identify new treatment targets for this important complication. The investigator hypothesizes that low-dose GH administration for 18 months will improve skeletal health.

Conditions

• Obesity
• Osteopenia

Interventions

Type	Name	Description
DRUG	Growth hormone
DRUG	Placebo

Timeline

• Start date: 2013-08-01
• Primary completion: 2018-11-15
• Completion: 2019-04-01
• First posted: 2012-11-09
• Last updated: 2019-12-17
• Results posted: 2019-12-17

Locations

1 site across 1 country: United States